With the global increase of sexually transmitted infections (STIs), the need for accessible and accurate STI diagnostic solutions has never been more critical. Traditional testing methods are hindered by several barriers, including limited accessibility and STI-related stigma. This is further compounded by the challenge of asymptomatic infections, which deter initial testing. However, the unprecedented adoption of at-home testing and telemedicine that developed during the COVID-19 pandemic has facilitated the expansion of at-home and self-collection assays for several diseases, such as STIs. Join us as we delve into the changing landscape of STI testing, highlighting the new developments in at-home testing and the molecular and immunoassay reagent solutions for developing new STI assays.

IN THIS WEBINAR, YOU WILL LEARN ABOUT:

• What has changed in STI testing in the post-COVID market and the key differences between home-testing vs. self-collection assays
• Innovative molecular chemistries that enable sensitive direct detection using crude samples
• High-performing immuno-reagents ideal for rapid lateral flow tests
• The future direction of STI screening: trends and growth predictions

Speakers:

Steve Hawkins, Ph.D., Merdian Life Science Molecular Product Manager

Ryan Hughes, Ph.D, Merdian Life Science Immuno Product Manager

The molecular diagnostic approach for infectious disease such as STDs, tropical, and respiratory disease has seen significant development in the past twelve months, driven by a demand for better, faster, higher sensitivity assays, that can detect asymptomatic carriers. Traditionally, lab-based tests using blood samples have been the mainstay for molecular testing, however home-based, extraction-free tests, using alternative sample types (saliva, urine, stool) are now highly sought after, but pose significant challenges in assay development for both lab-based and point of care (POC) applications.

In this webinar you will learn about:

• New nucleic acid amplification chemistries that simplify direct detection
• Optimizing assay performance per sample types (e.g. blood, saliva, urine, stool)
• The latest technologies that can reduce your cold-chain management

Presenters
Michele Amasio, Ph.D.
Research and Development Senior Manager

Steve Hawkins
Ph.D. – Product Marketing Manager